Florida is currently home to 3783 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Recruiting
This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Mayo Clinic-Jacksonville, Jacksonville, Florida
Conditions: Extensive Stage-small Cell Lung Cancer
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Recruiting
The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to three dose levels in adult participants aged 18 to 45 years with moderate to severe acne.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
06/13/2025
Locations: Universal Medical Research-Coral Gables Office- Site Number : 8400081, Coral Gables, Florida
Conditions: Acne
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
Recruiting
This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will be enrolled after a sentinel cohort of adults is complete.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: NOE-TTS-201 Site #71, Deland, Florida
Conditions: Tourette Syndrome
A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
Recruiting
This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM). The study duration will be approximately 92 weeks for all participants. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either empasiprubart or placebo, respectively, during the treatment period (duration of 25 weeks). At the end of the treatment period, all the participants will enter a safety follow-up period (d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Omega Research Debary, LLC, Debary, Florida
Conditions: Dermatomyositis, Myositis
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Recruiting
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransfe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Lake Mary Cancer Center - Florida Cancer Specialists & Research Institute, Lake Mary, Florida
Conditions: MTAP-deleted Solid Tumors
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Recruiting
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Zai Lab Site 2026, Sarasota, Florida
Conditions: SCLC
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Recruiting
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Florida Cancer Specialists and Research Institute, Lake Mary, Florida
Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
Recruiting
This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.
Gender:
ALL
Ages:
All
Trial Updated:
06/13/2025
Locations: University of Florida - Neurology, Gainesville, Florida
Conditions: Friedreich Ataxia
Safety and Feasibility of the ELIOS System in POAG Patients
Recruiting
Evaluation of the safety and effectiveness of the ELIOS System procedure to reduce intraocular pressure (IOP) in adult subjects with mild to moderate primary open-angle glaucoma (POAG)
Gender:
ALL
Ages:
45 years and above
Trial Updated:
06/13/2025
Locations: Elios Vision Clinical Site, Largo, Florida
Conditions: Glaucoma, Primary Open Angle
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Recruiting
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is be... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
06/13/2025
Locations: Arnold Palmer Hospital for Children Center Digestive Health & Nutrition - Orland /ID# 255437, Orlando, Florida
Conditions: Crohn's Disease
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
Recruiting
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: Advent Health Orlando Hospital, Orlando, Florida
Conditions: Cachexia
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
Recruiting
This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular atrophy (SMA) and 2 SMN2 copies who have previously received onasemnogene abeparvovec. Participants are children \< 2 years of age genetically diagnosed with SMA.
Gender:
ALL
Ages:
Between 3 months and 24 months
Trial Updated:
06/13/2025
Locations: University of Florida Pediatrics, Gainesville, Florida
Conditions: Muscular Atrophy, Spinal